Your search returned 23 results.

Results
	21.	Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. [electronic resource] by Coles, Alasdair J Cohen, Jeffrey A Fox, Edward J Giovannoni, Gavin Hartung, Hans-Peter Havrdova, Eva Schippling, Sven Selmaj, Krzysztof W Traboulsee, Anthony Compston, D Alastair S Margolin, David H Thangavelu, Karthinathan Chirieac, Madalina C Jody, Darlene Xenopoulos, Panos Hogan, Richard J Panzara, Michael A Arnold, Douglas L Producer: 20170915 In: Neurology vol. 89 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	22.	Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy. [electronic resource] by Havrdova, Eva Arnold, Douglas L Cohen, Jeffrey A Hartung, Hans-Peter Fox, Edward J Giovannoni, Gavin Schippling, Sven Selmaj, Krzysztof W Traboulsee, Anthony Compston, D Alastair S Margolin, David H Thangavelu, Karthinathan Rodriguez, Claudio E Jody, Darlene Hogan, Richard J Xenopoulos, Panos Panzara, Michael A Coles, Alasdair J Producer: 20170915 In: Neurology vol. 89 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	23.	Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. [electronic resource] by Cohen, Jeffrey A Coles, Alasdair J Arnold, Douglas L Confavreux, Christian Fox, Edward J Hartung, Hans-Peter Havrdova, Eva Selmaj, Krzysztof W Weiner, Howard L Fisher, Elizabeth Brinar, Vesna V Giovannoni, Gavin Stojanovic, Miroslav Ertik, Bella I Lake, Stephen L Margolin, David H Panzara, Michael A Compston, D Alastair S Producer: 20121210 In: Lancet (London, England) vol. 380 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)